KR100609359B1 - 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 - Google Patents

위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 Download PDF

Info

Publication number
KR100609359B1
KR100609359B1 KR1020007001703A KR20007001703A KR100609359B1 KR 100609359 B1 KR100609359 B1 KR 100609359B1 KR 1020007001703 A KR1020007001703 A KR 1020007001703A KR 20007001703 A KR20007001703 A KR 20007001703A KR 100609359 B1 KR100609359 B1 KR 100609359B1
Authority
KR
South Korea
Prior art keywords
composition
gabapentin
compound
gastrointestinal
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007001703A
Other languages
English (en)
Korean (ko)
Other versions
KR20010023084A (ko
Inventor
안토니오 구글리에타
챨스 프라이스 쥬니어 테일러
지아유안 렌
더블유. 피. 왓슨
마이클 프란시스 래퍼티
라우렌 디오프
마리아 쇼베
리오넬 부에노
힐러리 제이. 리틀
Original Assignee
워너-램버트 캄파니 엘엘씨
더 유니버시티 오브 오클라호마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100609359(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 워너-램버트 캄파니 엘엘씨, 더 유니버시티 오브 오클라호마 filed Critical 워너-램버트 캄파니 엘엘씨
Publication of KR20010023084A publication Critical patent/KR20010023084A/ko
Application granted granted Critical
Publication of KR100609359B1 publication Critical patent/KR100609359B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020007001703A 1997-08-20 1998-08-18 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체 Expired - Fee Related KR100609359B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5675397P 1997-08-20 1997-08-20
US60/056,753 1997-08-20
US7479498P 1998-02-16 1998-02-16
US60/074,794 1998-02-16
US8293698P 1998-04-24 1998-04-24
US60/082,936 1998-04-24
PCT/US1998/017082 WO1999008671A1 (en) 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020057022543A Division KR20050116168A (ko) 1997-08-20 1998-08-18 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체

Publications (2)

Publication Number Publication Date
KR20010023084A KR20010023084A (ko) 2001-03-26
KR100609359B1 true KR100609359B1 (ko) 2006-08-04

Family

ID=27369092

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020007001703A Expired - Fee Related KR100609359B1 (ko) 1997-08-20 1998-08-18 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체
KR1020057022543A Ceased KR20050116168A (ko) 1997-08-20 1998-08-18 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057022543A Ceased KR20050116168A (ko) 1997-08-20 1998-08-18 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체

Country Status (25)

Country Link
US (2) US6242488B1 (enExample)
EP (1) EP1009399B1 (enExample)
JP (1) JP4681116B2 (enExample)
KR (2) KR100609359B1 (enExample)
AT (1) ATE461698T1 (enExample)
AU (2) AU8668598A (enExample)
BR (1) BR9812133A (enExample)
CA (1) CA2297163C (enExample)
CO (1) CO4960645A1 (enExample)
CY (1) CY1109981T1 (enExample)
DE (1) DE69841574D1 (enExample)
DK (1) DK1009399T3 (enExample)
ES (1) ES2341154T3 (enExample)
HU (1) HUP0004551A3 (enExample)
IL (1) IL134164A (enExample)
IS (1) IS2749B (enExample)
MY (1) MY155223A (enExample)
NO (1) NO327983B1 (enExample)
NZ (1) NZ502729A (enExample)
PE (1) PE107299A1 (enExample)
PL (1) PL194125B1 (enExample)
PT (1) PT1009399E (enExample)
TW (2) TWI251485B (enExample)
UY (1) UY25148A1 (enExample)
WO (2) WO1999008670A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
DK1011658T3 (da) 1997-09-08 2006-04-03 Warner Lambert Co Analgesiske præparater, der omfatter antiepileptiske forbindelser, og fremgangsmåder til anvendelse af samme
EP1031350A1 (en) * 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
JP2002538221A (ja) * 1999-03-10 2002-11-12 ワーナー−ランバート・カンパニー 抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
DK1169060T3 (da) * 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
DE60034344T2 (de) 1999-07-22 2008-01-10 University Of Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
JP2003533223A (ja) * 2000-05-16 2003-11-11 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー α２δ２カルシウムチャネルサブユニットの発現細胞株
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1343805A4 (en) 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345638A1 (en) 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
DK1404324T4 (da) 2001-06-11 2011-07-11 Xenoport Inc Prolægemidler af GABA analoger, sammensætninger og anvendelser deraf
PT1423168E (pt) * 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
JP2005523281A (ja) * 2002-02-22 2005-08-04 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アルファ−２−デルタリガンドとシクロオキシゲナーゼ−２の選択的阻害剤との組合せ
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
JP2005533100A (ja) * 2002-07-10 2005-11-04 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｇａｂａ誘導体を含む胃腸用組成物
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PL377657A1 (pl) * 2002-12-13 2006-02-06 Warner-Lambert Company Llc Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
KR100845932B1 (ko) * 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체
CA2518218A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc Tetrazole and oxadiazolone substituted .beta.-amino acid derivatives
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
US8114909B2 (en) 2003-09-17 2012-02-14 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
ATE516801T1 (de) 2003-10-14 2011-08-15 Xenoport Inc Kristalline form eines gamma-aminobuttersäure- analogons
EP2343073A3 (en) 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
KR100823758B1 (ko) * 2004-03-12 2008-04-21 워너-램버트 캄파니 엘엘씨 Ｃ1-대칭 비스포스핀 리간드 및 프레가발린의 비대칭합성에서의 이들의 용도
BRPI0508998A (pt) * 2004-04-01 2007-09-04 Warner Lambert Co preparação de fosfolanos p-quirogênicos e seu uso em sìntese assimétrica
CN102102114B (zh) * 2004-06-21 2013-08-14 沃尼尔·朗伯有限责任公司 普瑞巴林和相关化合物的制备
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
SI1963280T1 (sl) * 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2101752A1 (en) * 2006-12-08 2009-09-23 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
AU2008317336A1 (en) * 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
EP2250143B1 (en) 2008-01-25 2016-04-20 XenoPort, Inc. Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN102216257B (zh) 2008-10-08 2015-11-25 凯飞药业公司 Gaba偶联物及其使用方法
EP2445486B1 (en) * 2009-06-22 2017-11-08 Wyeth LLC Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
HUE047629T2 (hu) 2013-01-28 2020-05-28 Lopez Hector L Eljárások ß-alanin tolerancia, farmakodinamika és hatékonyság javítására és azok alkalmazása
CN105997970A (zh) * 2015-12-16 2016-10-12 南昌大学 γ-氨基丁酸在制备胃粘膜保护剂中的应用
WO2017177160A1 (en) * 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
CA3075414A1 (en) 2017-10-03 2019-04-11 Nevakar Inc. Acetaminophen-pregabalin combinations and methods of treating pain
KR102750784B1 (ko) 2018-05-14 2025-01-06 엑스진 파마슈티컬 인크. 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 제조방법 및 그 중간체
CN116999560A (zh) * 2022-04-30 2023-11-07 武汉思瓴生物科技有限公司 可治疗疼痛的药物组合及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634102A (enExample)
DE1963925C3 (de) 1969-12-20 1975-07-10 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins
JPS54110334A (en) 1978-02-16 1979-08-29 Fuji Chem Ind Co Ltd Novel compounded anodyne and antiiinflammatory agent
US4158581A (en) 1978-04-14 1979-06-19 Westinghouse Electric Corp. Method of making magnetic component for direct current apparatus
JPS61221121A (ja) 1985-03-27 1986-10-01 Nitto Electric Ind Co Ltd テ−プ製剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
AU2929489A (en) 1987-12-22 1989-07-19 John W. FERKANY Dextrorphan potentiator for anticonvulsant composition and method
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en) 1991-04-18 1991-06-05 Radoslavov Alexander A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
AU677008B2 (en) 1992-05-20 1997-04-10 Northwestern University Gaba and L-glutamic acid analogs for antiseizure treatment
US5234929A (en) 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja) 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd 徐放性組成物
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja) 1993-02-02 1994-08-16 Masayasu Sugihara 薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en) 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
WO1996007412A1 (en) 1994-09-02 1996-03-14 Virginia Commonwealth University Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
CN1046199C (zh) 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
ATE293458T1 (de) * 1996-08-23 2005-05-15 Algos Pharm Corp Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
DE69737719D1 (de) * 1996-10-23 2007-06-21 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
US20010014698A1 (en) 2001-08-16
HUP0004551A3 (en) 2002-11-28
DE69841574D1 (de) 2010-05-06
MY155223A (en) 2015-09-30
US6242488B1 (en) 2001-06-05
US6426368B2 (en) 2002-07-30
WO1999008670A1 (en) 1999-02-25
ES2341154T3 (es) 2010-06-15
UY25148A1 (es) 1999-01-26
IS5361A (is) 2000-01-25
NO20000786D0 (no) 2000-02-17
WO1999008671A1 (en) 1999-02-25
PE107299A1 (es) 1999-12-19
TW570794B (en) 2004-01-11
ATE461698T1 (de) 2010-04-15
JP4681116B2 (ja) 2011-05-11
KR20010023084A (ko) 2001-03-26
AU8668598A (en) 1999-03-08
TW200412938A (en) 2004-08-01
CY1109981T1 (el) 2014-09-10
DK1009399T3 (da) 2010-05-31
TWI251485B (en) 2006-03-21
IL134164A0 (en) 2001-04-30
EP1009399B1 (en) 2010-03-24
AU9293098A (en) 1999-03-08
CA2297163C (en) 2001-11-20
EP1009399A1 (en) 2000-06-21
CO4960645A1 (es) 2000-09-25
NO327983B1 (no) 2009-11-02
JP2001515033A (ja) 2001-09-18
IS2749B (is) 2011-08-15
IL134164A (en) 2005-05-17
KR20050116168A (ko) 2005-12-09
NZ502729A (en) 2002-10-25
PT1009399E (pt) 2010-05-21
NO20000786L (no) 2000-02-17
BR9812133A (pt) 2000-07-18
HUP0004551A2 (hu) 2001-05-28
PL338705A1 (en) 2000-11-20
CA2297163A1 (en) 1999-02-25
PL194125B1 (pl) 2007-04-30

Similar Documents

Publication Publication Date Title
KR100609359B1 (ko) 위장 손상의 예방 및 치료를 위한감마-아미노부티르산(ｇａｂａ) 동족체
US6127418A (en) GABA analogs to prevent and treat gastrointestinal damage
JP3018135B2 (ja) 鎮痛剤
US6426338B1 (en) Therapy for constipation
FR2559061A1 (fr) Compositions analgesiques et anti-inflammatoires contenant de la diphenhydramine
HUP0200344A2 (hu) Gabapentinszármazék alkalmazása visceralis fájdalom megelőzésére és kezelésére
Peng et al. Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs
Sugimoto et al. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin
JP7328153B2 (ja) 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物
FR2931677A1 (fr) Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
HRP20020286A2 (en) Synergistic combinations of an nk<sub>1</sub> receptor antagonist and a gaba structural analog
EP0974351A2 (en) Medicament for preventing and treating gastrointestinal damage
AU2002317548B2 (en) Gaba analogs to prevent and treat gastrointestinal damage
Xu et al. Mitigative effects of dehydrodiisoeugenol on enteritis and co-occurring dysmotility in murine model.
Gerring Effects of pharmacological agents on gastrointestinal motility
MXPA00001093A (en) Gaba analogs to prevent and treat gastrointestinal damage
RU2527683C1 (ru) Способ профилактики и лечения язвенной болезни желудка, вызываемой стрессом
KR102625977B1 (ko) 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
CN1649590A (zh) 包含拉呋替丁的治疗剂
Malfertheiner et al. Effects of microencapsulated vs. enteric-coated acetylsalicylic acid on gastric and duodenal mucosa: an endoscopic study
ES2325824A1 (es) Utilizacion de valproato para el tratamiento del miedo y la fobia en sujetos con la enfermedad de alzheimer.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20110629

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120729

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120729

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000